Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917170 | 0.88 | HSD17B10 (0.58) | HSD17B10MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL946410 | 0.88 | HSD17B10 (0.58) | HSD17B10MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL1434303 | 0.88 | HSD17B10 (0.58) | HSD17B10MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL11592794 | 0.88 | HSD17B10 (0.58) | HSD17B10MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL915309 | 0.88 | HSD17B10 (0.58) | HSD17B10MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL16445915 | 0.88 | HSD17B10 (0.58) | HSD17B10MEN1KMT2ATSHRMAPK1 | |
| Triethylene Glycol SCHEMBL9463125 | 0.87 | HSD17B10 (0.45) | HSD17B10MEN1KMT2ATSHRMAPK1 | |
| Succinic Acid SCHEMBL28086985 | 0.87 | HSD17B10 (0.45) | HSD17B10MEN1KMT2ATSHRMAPK1 | |
| Acetic Acid SCHEMBL8940147 | 0.86 | HSD17B10 (0.52) | HSD17B10MEN1KMT2ATSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL5860540 | 0.86 | HSD17B10 (0.56) | HSD17B10MEN1KMT2ATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613343-B1 | INSULIN POLYPEPTIDE-OLIGOMER CONJUGATES, PROINSULIN POLYPEPTIDE-OLIGOMER CONJUGATES AND METHODS OF SYNTHESIZING SAME | BIOCON LTD (IN) | 2016-12-07 | — | — | EP | disclosed |
| US-7611864-B2 | Proinsulin polypeptide-oligomer conjugates | BIOCON LIMITED (IN) | 2009-11-03 | — | — | US | disclosed |
| EP-1430082-B1 | METHODS OF SYNTHESIZING INSULIN POLYPEPTIDE-OLIGOMER CONJUGATES, AND PROINSULIN POLYPEPTIDE-OLIGOMER CONJUGATES AND METHODS OF SYNTHESIZING SAME | BIOCON LTD (IN) | 2009-10-28 | — | — | EP | disclosed |
| US-7368260-B2 | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same | BIOCON LIMITED (IN) | 2008-05-06 | — | — | US | disclosed |
| EP-1613343-A4 | INSULIN POLYPEPTIDE-OLIGOMER CONJUGATES, PROINSULIN POLYPEPTIDE-OLIGOMER CONJUGATES AND METHODS OF SYNTHESIZING SAME | BIOCON LTD (IN) | 2008-03-05 | — | — | EP | disclosed |
| US-7312192-B2 | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same | BIOCON LIMITED (IN) | 2007-12-25 | — | — | US | disclosed |
| US-7196059-B2 | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith | BIOCON LIMITED (IN) | 2007-03-27 | — | — | US | disclosed |
| US-7166571-B2 | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same | BIOCON LIMITED (IN) | 2007-01-23 | — | — | US | disclosed |
| US-7030082-B2 | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith | NOBEX CORPORATION (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1613343-A2 | INSULIN POLYPEPTIDE-OLIGOMER CONJUGATES, PROINSULIN POLYPEPTIDE-OLIGOMER CONJUGATES AND METHODS OF SYNTHESIZING SAME | Nobex Corporation (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040038866-A1 | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith | BIOCON LIMITED (IN) | 2004-02-26 | — | — | US | disclosed |
| US-20040017387-A1 | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith | BIOCON LIMITED (IN) | 2004-01-29 | — | — | US | disclosed |
| US-20030228652-A1 | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same | NOBEX CORPORATION | 2003-12-11 | — | — | US | disclosed |
| US-20030229009-A1 | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same | BIOCON LIMITED (IN) | 2003-12-11 | — | — | US | disclosed |
| US-20030087808-A1 | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same | BIOCON LIMITED (IN) | 2003-05-08 | — | — | US | disclosed |
| US-20030083232-A1 | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith | BIOCON LIMITED (IN) | 2003-05-01 | — | — | US | disclosed |
| US-20030069170-A1 | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith | BIOCON LIMITED (IN) | 2003-04-10 | — | — | US | disclosed |
| WO-2003022210-A2 | PHARMACEUTICAL COMPOSITIONS OF DRUG-OLIGOMER CONJUGATES AND METHODS OF TREATING DISEASES THEREWITH | NOBEX CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003022208-A2 | PHARMACEUTICAL COMPOSITIONS OF INSULIN DRUG-OLIGOMER CONJUGATES AND METHODS OF TREATING DISEASES THEREWITH | NOBEX CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003022996-A2 | METHODS OF SYNTHESIZING INSULIN POLYPEPTIDE-OLIGOMER CONJUGATES, AND PROINSULIN POLYPEPTIDE-OLIGOMER CONJUGATES AND METHODS OF SYNTHESIZING SAME | NOBEX CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087808-A1 | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same | IAPP, GCG, INSR | HSD17B10 2015/4885MEN1 68/4885KMT2A 4573/4885 |
| US-20030228652-A1 | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same | IAPP, INSR, INSRR | HSD17B10 2301/4885MEN1 60/4885KMT2A 4638/4885 |
| US-20030069170-A1 | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith | SLC10A1, SLC10A2, NR1H4 | HSD17B10 54/4885MEN1 2319/4885KMT2A 4247/4885 |
| US-20030229009-A1 | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same | IAPP, INSR, INSRR | HSD17B10 2301/4885MEN1 60/4885KMT2A 4638/4885 |
| US-20040038866-A1 | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith | IAPP, INSR, SLC10A1 | HSD17B10 38/4885MEN1 580/4885KMT2A 4472/4885 |
| US-20030083232-A1 | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith | IAPP, INSR, SLC10A1 | HSD17B10 46/4885MEN1 720/4885KMT2A 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.